Sign in
TerminatedPhase 1

A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002

Key facts

Who runs it
Yisheng Biopharma (Singapore) Pte. Ltd.
Where
Philippines1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
16 people enrolled
Started
1 Jul 2024
Ended
31 Oct 2024
Type of study
Interventional, 3 groups
Treatments tested
  • YS-HBV-002
Record updated
24 February 2025
Why it stopped
Business strategy

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (27)Hide the full registry criteria

Who can take part

  • Age ≥ 18 years during screening
  • Body Mass Index (BMI) of 18.5-30 kg/m2
  • Diagnosed or laboratory confirmed to have CHB; Have CHB infection for at least 6 months; HBsAg titer ≥ 1000 IU/mL; HBV DNA ≥ 2000 IU/mL; Serum alanine amino transferase (ALT) and aspartate aminotransferase (AST) ≤ 2 × upper limit of normal (ULN)
  • Able to provide informed consent
  • Able and willing to comply with all study procedures throughout the study period of approximately 3 months
  • For female subjects with childbearing potential: must agree to avoid pregnancy throughout the study period of approximately 3 months. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods on avoiding pregnancy include: a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with a spermicide

Who cannot take part

  • Transient elastography at screening revealing a FibroScan value of ≥ 9 kPa or a previous liver biopsy evidencing hepatic fibrosis at or within 24 months prior to vaccination
  • Vaccinated with live attenuated vaccine within 1 month, or other vaccine/non-COVID-19 vaccine within 14 days prior to vaccination
  • Receiving immunotherapy or inhibitor therapy (consistently oral or infusion for more than 14 days) within 3 months prior to vaccination
  • Received systemic immunosuppressants within 4 months prior to vaccination or anticipating the need for immunosuppressant at any time during participation in the study. Topical or inhaled treatment is allowed if not used within 14 days prior to vaccination
  • Have received antiviral therapy for chronic hepatitis but have stopped for less than 30 days or plan to take antiviral therapy during the study
  • Received blood products within 3 months before vaccine administration
  • Patients with hepatitis caused by other etiologies
  • History of or manifestations of liver decompensation (e.g., Child-Pugh Class B or C, or ascites, gastrointestinal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, etc....)
  • History of severe allergic reactions (such as acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema, or allergic abdominal pain) or allergy to any of the components of YS-HBV-002
  • Any history of anaphylaxis or angioedema after any vaccination
  • Allergy to kanamycin and aminoglycosides
  • Past or family history of convulsion, epilepsy, encephalopathy, or mental illness
  • Diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia, or other autoimmune diseases
  • History of coagulation dysfunction (e.g., coagulation factor deficiency, coagulation disease)
  • Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating IM vaccination based on the investigator's judgement
  • History of alcohol or drug abuse within the past 2 years
  • Any condition that, in the opinion of the investigator, would pose a health risk to the patient if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results
  • Pregnant or breastfeeding or intending to become pregnant within the projected duration of the trial
  • Currently participating in or has participated in a study with an IP within 30 days preceding Day 0
  • Fever (axillary temperature ≥ 37.8 ℃)
  • Subjects with abnormal indicators of blood biochemistry and other routine blood tests deemed clinically significant by the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is the first-in-human Phase I, double-blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, immunogenicity and preliminary efficacy of the YSHBV-002 in the treatment of CHB in adults ≥18 years old. There will be 3 escalating doses of YS-HBV-002 to be administered intramuscularly: 0.5mL, 1.0mL, and 2.0mL.

The 3 groups in the trial

  • Low dose 0.5mLTreatment being tested

    Group A :The first 4 enrollees in Group A will be sentinel patients and will be allocated at a 1:1 ratio to receive 0.5mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 0.5mL of either YS-HBV-002 or placebo.

    Treatment: YS-HBV-002

  • Mid-dose 1.0mLTreatment being tested

    Group B :The first 4 enrollees in Group B will be sentinel patients and will be allocated at a 1:1 ratio to receive 1.0mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 1.0mL of either YS-HBV-002 or placebo.

    Treatment: YS-HBV-002

  • High dose 2.0mLTreatment being tested

    Group C :The first 4 enrollees in Group C will be sentinel patients and will be allocated at a 1:1 ratio to receive 2.0mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 2.0mL of either YS-HBV-002 or placebo.

    Treatment: YS-HBV-002

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I, Double-blind, Randomized, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 in the Treatment of Chronic Hepatitis B (CHB) Infection in Adults ≥ 18 Years Old
Record updated
24 February 2025